US Gov Medical Experiment Radically Departs from medical “Best Practices”
The NY Times reports that an IMS Health report found that the giant pharmaceutical industry annual growth of pharma sales in the US and Western Europe has slowed to the low single digits in the last 8...
View ArticleGlaxo Is Testing Paxil on 7-Year-Olds Despite Well Known Suicide Risks
A report in BNET, the business publication, by its pharmaceutical industry analyst, Jim Edwards, reveals that GlaxoSmithKline is conducting a clinical trial to test its dubious antidepressant, Paxil,...
View ArticleWill Another Blockbuster Drug Hit the Dust?
In 2007, an FDA advisory panel voted 22 to 1 to keep GlaxoSmithKline’s diabetes drug, Avandia (Rosiglitazone) on the market–albeit with a black box warning label. This week, that panel (now...
View ArticleFDA Expands Market for Another Toxic Antipsychotic
According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics...
View ArticleClik here to view.
FDA MedWatch- Antipsychotics Class Label Change
The FDA has just issued an alert to healthcare professionals–in particular, psychiatrists and obstetricians about the serious risks posed by antipsychotic drugs for newborn infants: "The symptoms of...
View ArticleUS Inspector General Report: Antipsychotic Drug Hazards
Antipsychotics are used primarily as chemical restraints to control behavior– not for any therapeutic, medically justifiable reason.. The claimed benefit for patients has never been supported by...
View ArticleClik here to view.
America’s Healthcare Crisis–Part II–What Do We Get for $$$ ?
IV. What Do We Get for All That Money? According to the Kaiser Foundation:[1] The number of prescriptions filled in the US increased 72% from 1997 to 2007. US prescriptions rose to 3.9 billion in 2009...
View ArticleClik here to view.
A Bad Judicial Decision Undercuts Drug Safety Law
On December, 3, in a 2 to 1 decision, the US Court of Appeals for the Second Circuit (New York) overturned the conviction of Alfred Caronia, a pharmaceutical company sales representative who was...
View ArticleClik here to view.
David Graham, MD
David Graham, MD, FDA’s Associate Director of Science and Medicine who, throughout his career, has been a thorn for FDA managers by identifying hazardous drug effects. In 1999, his data helped identify...
View ArticleClik here to view.
Testimony Against SF 2841-Minnesota – Preschool Socioemotional...
Karen R. Effrem, MD EdWatch Board of Directors Alliance for Human Research Protection Board of Directors ICSPP Board of Directors Thank you Mr. Chairman and members of the Committee. My name is Dr....
View Article
